Thomas J. Mcgahren Email & Phone Number

New York, Ny, Us

Life sciences investment banker advising private and public biotech, pharma, spec pharma, medtech and diagnostic companies in financing, M&A and strategic matters. Leveraging diverse skill sets, unique educational background (MD, JD), bulge bracket biotech sell-side analyst experience, legal experience representing life science companies at large international law firm, extensive life science industry, venture capital and Wall Street investment community network to provide strategic analysis and advice particularly for companies with cutting-edge science and "change the world" ambitions. Expert at discerning what constitutes biotech "investible propositions," seeking investment, M&A and collaborative opportunities. Particular interest in companies utilizing synthetic biology, cell and gene therapy, to address unmet medical needs. Experience incubating companies, including the company that because Avexis (AVXS) (acquired by Novartis), provided basis for launching Agilis Biotherapeutics (www.agilisbio.com), focused on gene therapy for rare CNS diseases. (Member of founding group and Scientific Advisory Board of Agilis). Significant work for companies active in synthetic biology such as (XON) and its collaborating companies. Also asked to consult for Celgene on its acquisitions prior to joining Griffin.

Member of founding group and Scientific Advisory Board (SAB) of Agilis Biotherapeutics, www.agilisbio.com, a biotechnology company focused on designing and engineering first-in-class gene therapy to address rare CNS diseases. (Acquired by PTC Therapeutics (PTCT) Aug. 2018). Lead candidate, AGIL-AADC is pre-BLA for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency. The company received a Rare Pediatric Disease designation, which would entitle it to a Priority Review Voucher upon approval of AGIL-AADC. Pipeline candidates include AGIL-FA for Friedreich ataxia (partnered with Intrexon (NYSE: XON)) and AGIL-AS for Angelman Syndrome. Agilis is currently conducting a Series C financing. The launch of Agilis was based on extensive analysis of potential rare disease indications, therapeutic options and licensing possibilities. Actively participated in sourcing and securing the science, management, financing, licensing, collaborations, trademark/logo etc.

Greensboro, Nc, Us

Assisted with assessment and due diligence of potential life sciences investment opportunities for early state VC fund formed by alumni of Colgate University. Leveraged medical, legal and Wall Street biotech analyst background.

New York, Ny, Us

Senior Director, Senior Biotechnology Analyst. Forbes #1 Drugs Analyst ranking 2008. Responsible for all aspects of sell-side research: due diligence, launching coverage, financial modeling, industry analysis, surveys, Merrill Lynch health conferences, marketing, roadshows, medical conferences, court hearings, deal vetting, collaboration with capital markets and derivative teams. Leveraged particular expertise in medical, legal, IP, FDA, and regulatory issues. Routinely consulted by other Merrill health science equity research teams, particularly on IP and legal matters. Covered or supervised coverage of large, mid and small cap biotechnology companies including CELG, GENZ, AMGN, BIIB, BMRN, AMLN, OSIP, OREX, ARNA, ALTU, PDLI, MLNM, KERX, ALTH, AFFY, ONXX, COLY, RIGL. Representative speaking engagements: "Valuation of Patent Protected Biotech Products," ACI (American Conf. Institute 2006; "Building IP Asset Management Competency," Northwestern Kellogg Biotech Conf 2005

Charlotte, Nc, Us

Associate biotechnology analyst on II-ranked team covering large, mid and small cap companies. Drafted initiations, event and earnings notes. Routinely consulted by other BofA analysts, particularly on IP, FDA, medical issues in view of expertise and experience as a physician and attorney representing biotech and big pharma companies as a litigator.

Litigator representing pharmaceutical, biotechnology and med-tech companies in intellectual property, FDA and corporate matters at major international law firm. Developed expertise in biopharma industry, FDA practice & procedure and particularly biotech intellectual property litigation. Participated in all phases of litigation, counseling and business development. Conducted due diligence regarding IP aspects of corporate transactions. Representative clients included, e.g., Pfizer, Chiron, Bristol Myers, Johnson&Johnson. Recruited from law firm by Banc of America Securities to join top-ranked biotech equity research team.

Jd

Md

Ba, Political Science